A promising medication, the drug , is sparking significant buzz within the healthcare community as a anticipated treatment for weight challenges. Designed by Eli Lilly , it’s a twin GIP and GLP-1 target agonist, meaning it functions on two different pathways to regulate appetite and promote metaboli